Joshua E. Allen

5.1k total citations
125 papers, 2.5k citations indexed

About

Joshua E. Allen is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Joshua E. Allen has authored 125 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Molecular Biology, 54 papers in Oncology and 34 papers in Genetics. Recurrent topics in Joshua E. Allen's work include Glioma Diagnosis and Treatment (34 papers), Cell death mechanisms and regulation (21 papers) and Cancer therapeutics and mechanisms (20 papers). Joshua E. Allen is often cited by papers focused on Glioma Diagnosis and Treatment (34 papers), Cell death mechanisms and regulation (21 papers) and Cancer therapeutics and mechanisms (20 papers). Joshua E. Allen collaborates with scholars based in United States, United Kingdom and China. Joshua E. Allen's co-authors include Wafik S. El‐Deiry, David T. Dicker, Varun V. Prabhu, C. Leah B. Kline, Wolfgang Oster, A. Pieter J. van den Heuvel, Patrick A. Mayes, Martin Stogniew, Nathan G. Dolloff and Wenge Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Joshua E. Allen

115 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua E. Allen United States	28	1.6k	671	476	393	268	125	2.5k
Georg Karpel‐Massler Germany	36	1.9k 1.2×	565 0.8×	785 1.6×	881 2.2×	351 1.3×	103	3.1k
Mike‐Andrew Westhoff Germany	38	2.5k 1.6×	765 1.1×	904 1.9×	803 2.0×	429 1.6×	102	3.9k
Patrick A. Mayes United States	17	1.4k 0.9×	1.2k 1.8×	521 1.1×	153 0.4×	586 2.2×	31	2.5k
Joy Fisher United States	23	1.1k 0.7×	524 0.8×	481 1.0×	1.2k 3.0×	192 0.7×	56	2.6k
Luna Musib United States	24	1.4k 0.9×	952 1.4×	342 0.7×	751 1.9×	104 0.4×	77	2.6k
Meike Vogler Germany	26	2.1k 1.3×	769 1.1×	362 0.8×	396 1.0×	563 2.1×	59	2.9k
Dimpy Koul United States	33	2.6k 1.6×	877 1.3×	892 1.9×	820 2.1×	364 1.4×	63	3.7k
Ali R. Jazirehi United States	29	1.4k 0.9×	915 1.4×	417 0.9×	397 1.0×	581 2.2×	63	2.7k
Thelma S. Angeles United States	29	1.5k 0.9×	616 0.9×	212 0.4×	271 0.7×	195 0.7×	75	2.6k

Countries citing papers authored by Joshua E. Allen

Since Specialization

Citations

This map shows the geographic impact of Joshua E. Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua E. Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua E. Allen more than expected).

Fields of papers citing papers by Joshua E. Allen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua E. Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua E. Allen. The network helps show where Joshua E. Allen may publish in the future.

Co-authorship network of co-authors of Joshua E. Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua E. Allen. A scholar is included among the top collaborators of Joshua E. Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua E. Allen. Joshua E. Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carter, Jenna L., Yongwei Su, Jianlei Zhao, et al.. (2025). ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress. Journal of Experimental & Clinical Cancer Research. 44(1). 10–10.

Allen, Joshua E., et al.. (2024). Leiomyosarcoma of the Mandible. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 138(2). e45–e46.

Arrillaga‐Romany, Isabel, Andrew B. Lassman, Susan L. McGovern, et al.. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology. 26(Supplement_2). S173–S181. 25 indexed citations

Odia, Yazmín, Matthew D. Hall, Timothy F. Cloughesy, et al.. (2024). Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-Oncology. 26(Supplement_2). S165–S172. 4 indexed citations

Lee, Andrew, Scott A. Foster, Sara Morrow, et al.. (2023). Abstract 4914: Role of ClpP in the anti-cancer effects of imipridone ONC201 and ONC206. Cancer Research. 83(7_Supplement). 4914–4914. 1 indexed citations

Fan, Yali, Ziwei Fang, Katherine L. Tucker, et al.. (2022). Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer. Frontiers in Oncology. 12. 789450–789450. 14 indexed citations

Dwucet, Annika, Varun V. Prabhu, Joshua E. Allen, et al.. (2021). ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression. Frontiers in Cell and Developmental Biology. 9. 734699–734699. 3 indexed citations

Rahman, Rifaquat, Steffen Ventz, Irmarie Reyes‐Rivera, et al.. (2021). Leveraging external data in the design and analysis of clinical trials in neuro-oncology. The Lancet Oncology. 22(10). e456–e465. 52 indexed citations

Free, R. Benjamin, Yoon Namkung, Varun V. Prabhu, et al.. (2021). Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor. Molecular Pharmacology. 100(4). 372–387. 22 indexed citations

10.

He, Yuyu, Jie Li, Tomoyuki Koga, et al.. (2020). Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. Neuro-Oncology. 23(3). 400–411. 17 indexed citations

11.

Madhukar, Neel S., Prashant K. Khade, Linda Huang, et al.. (2019). A Bayesian machine learning approach for drug target identification using diverse data types. Nature Communications. 10(1). 161 indexed citations

12.

Zhang, Yiru, Elena Bianchetti, Chang Shu, et al.. (2018). Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clinical Cancer Research. 24(21). 5392–5406. 63 indexed citations

13.

Prabhu, Varun V., Bo Hong, Joshua E. Allen, et al.. (2016). Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation. Cancer Research. 76(7). 1989–1999. 49 indexed citations

14.

Allen, Joshua E., Varun V. Prabhu, Mala K. Talekar, et al.. (2015). Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75(8). 1668–1674. 35 indexed citations

15.

Prabhu, Varun V., Joshua E. Allen, David T. Dicker, & Wafik S. El‐Deiry. (2015). Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem–like Cells in an Akt/Foxo3a/TRAIL–Dependent Manner. Cancer Research. 75(7). 1423–1432. 113 indexed citations

16.

Lim, Bora, Joshua E. Allen, Varun V. Prabhu, et al.. (2015). Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion on Therapeutic Targets. 19(9). 1171–1185. 85 indexed citations

17.

Allen, Joshua E., Roger Ferrini, David T. Dicker, et al.. (2012). Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes. Molecular Cancer Therapeutics. 11(10). 2087–2095. 25 indexed citations

18.

Dolloff, Nathan G., Joshua E. Allen, David T. Dicker, et al.. (2012). Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. Molecular Cancer Therapeutics. 11(11). 2321–2330. 12 indexed citations

19.

Cheng, Hairong, Bo Hong, Lanlan Zhou, et al.. (2012). Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors. Cell Cycle. 11(17). 3312–3323. 28 indexed citations

20.

Mayes, Patrick A., Nathan G. Dolloff, Colin J. Daniel, et al.. (2011). Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3β and CDK1. Cancer Research. 71(15). 5265–5275. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact